AI Scans 400,000 Reddit Posts to Flag Overlooked GLP-1 Side Effects

Researchers at Penn Engineering developed an AI-based natural language processing system to analyze over 400,000 Reddit posts from nearly 70,000 users discussing GLP-1 medications (primarily semaglutide and tirzepatide). The study, published in Nature Health in April 2026, covered more than half a decade of posts.

The AI system was designed to identify and categorize symptom mentions in unstructured text — posts where users described their experiences in their own words, not structured adverse event reports. The system could distinguish between mentions of symptoms (someone saying they experienced nausea), discussions of symptoms (someone asking whether nausea is normal), and other references.

This approach captures the long tail of patient experience: symptoms that people mention in online communities but may not report to their physicians or that physicians may not submit as formal adverse events to the FDA.

The most commonly reported symptoms aligned with known GLP-1 side effects:

GI symptoms (expected): Nausea (36.9%), fatigue (16.7%), vomiting (16.3%), constipation (15.3%), diarrhea (12.6%). These are consistent with clinical trial data and FDA labeling.

Potentially underreported symptoms:

Reproductive/menstrual: Approximately 4% of users reported menstrual irregularities. The researchers note this would be an even higher percentage in a female-only sample. This finding aligns with tirzepatide’s known effect on progestin levels but extends the signal to the broader GLP-1 class.

Temperature-related: Chills and hot flashes were reported at rates that the researchers believe may be underrepresented in clinical trial data.

Psychiatric symptoms: Nearly 13% of users reported anxiety, depression, or insomnia. While psychiatric adverse events are monitored in clinical trials, the Reddit data suggests a potentially higher real-world incidence than trial data captures.

Clinical trials are the gold standard for drug safety assessment, but they have inherent limitations: finite sample sizes (typically 3,000–10,000 patients), defined monitoring periods, structured adverse event categories that may not capture all patient experiences, and populations that may not represent real-world diversity.

The Penn study demonstrates that social media pharmacovigilance can complement traditional safety monitoring by capturing symptoms from hundreds of thousands of users over years of real-world use. The AI approach can process unstructured text at scale and identify patterns that would be impossible to detect through manual review.

This matters for GLP-1 drugs specifically because tens of millions of people now take these medications worldwide. Even rare side effects at 1–2% incidence affect hundreds of thousands of patients. Identifying these early — even as signals rather than confirmed effects — allows researchers to design targeted studies and helps clinicians counsel patients more completely.

The researchers are clear that their findings are signal-generating, not conclusive. The symptoms identified warrant formal investigation in controlled studies, but should not be treated as confirmed drug side effects based on Reddit data alone.